Intellectual property rights and the life science industries: Past, present and future, 2nd edition

Intellectual Property Rights and the Life Science Industries: Past, Present and Future, 2nd Edition

Volumn , Issue , 2009, Pages 1-414

  Dutfield, Graham ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84973598016     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/6917     Document Type: Book

References (495)

1. Abbott, F.M. (2002) ‘The TRIPS Agreement, access to medicines, and the WTO Doha Ministerial Conference’. Journal of World Intellectual Property5 (1): 15-52.
2. Abbott, F.M. (2004) ‘The Doha Declaration on the TRIPS Agreement and Public Health and the contradictory trend in bilateral and regional free trade arrangements’. QUNO Occasional Paper 14. Geneva: Quaker United Nations Office.
3. Abbott, F.M. (2005) ‘The WTO medicines decision: World pharmaceutical trade and the protection of public health’. American Journal of International Law99: 317-358.
4. Abraham, E.P., E. Chain, C.M. Fletcher, H.W. Florey, A.D. Gardner, N.G. Heatley and M.A. Jennings (1941) ‘Further observations on penicillin’. The LancetAugust 16: 177-188.
5. Abraham, J. (2002) ‘The political economy of medicines regulation in Europe’, in H. Lawton-Smith (Ed.), The Regulation of Science and Technology.Basingstoke: Palgrave.
6. The Academy of Medical Science and the Royal Academy of Engineering (2007) ‘Systems biology: A vision for engineering and medicine’. London: AMS and RAE.
7. Acharya, R. (1999)The Emergence and Growth of Biotechnology: Experiences in Industrialised and Developing Countries. Cheltenham and Northampton: Edward Elgar.
8. Achilladelis, B. (1993) ‘The dynamics of technological innovation: The sector of antibacterial medicines’. Research Policy22: 279-308.
9. Aftalion, F. (1991) A History of the Chemical Industry.Philadelphia: University of Pennsylvania Press.
10. Aldhous, P. (1996) ‘Patent battle could hold up tests for cancer gene’. New Scientist13 January: 8.
11. Allarakhia, M. and A. Wensley (2007) ‘Systems biology: A disruptive biopharmaceutical research paradigm’. Technological Forecasting and Social Change74: 1643-1660.
12. American Pharmaceutical Association (1919) ‘Report of the Committee on Patents and Trademarks of the American Pharmaceutical Association, August 1919’. Journalofthe Patent Office Society2(1): 76-82.
13. Amyes, S.G.B. (2001)Magic Bullets, Lost Horizons: The Rise and Fall of Antibiotics. London and New York: Taylor and Francis.
14. Anderfelt, U. (1971)International Patent Legislation and Developing Countries. The Hague: Martinus Nijhoff.
15. Andrews, L. and D. Nelkin (2001)Body Bazaar: The Market for Human Tissue in the Biotechnology Age.New York: Crown Publishers.
16. Angell, M. (2004)The Truth about the Drug Companies: How They Deceive Us and What to Do about It.New York: Random House.
17. Apple, R. (1989) ‘Patenting university research: Harry Steenbock and the Wisconsin Alumni Research Foundation’. ISIS80(3): 375-394.
18. Ash, A.S.F. and H.O. Schild (1966) ‘Receptors mediating some actions of histamine’. Journal of Pharmacology and Chemotherapy27: 427-439.
19. Attaran, A. and L. Gillespie-White (2001) ‘Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?’Journal of the American Medical Association286(15): 1886-1892.
20. Austin, M. (2001) ‘Colo. AG sues 3 firms over drug’. Denver Post 28 September (http://www.denverpost.com/Stories/0,1002,33%257E161679,00.html).
21. Ball, P. (2007) ‘Life, but not as we know it’. Prospect August 44-47.
22. Ballance, R., J. Pogany and H. Forstner (1992)The World’s Pharmaceutical Industries: An International Perspective on Innovation, Competition and Policy. Prepared for the United Nations Industrial Development Organization.Aldershot: Edward Elgar.
23. Ballio, A., E.B. Chain, F. Dentice de Accadia, G.N. Rolinson and F.R. Batchelor (1959) ‘Pencillin derivatives of p-aminobenzylpenicillin’. Nature183: 180-181.
24. Barbanti, P, A. Gambardella and L. Orsenigo (1999) ‘The evolution of collaborative relationships among firms in biotechnology’. International Journal of Biotechnology1(1): 10-29.
25. Bardehle, H. (1999) ‘A new approach to worldwide harmonization of patent law’. Journal of the Patent and Trademark Office Society81 (4): 303-310.
26. Barthes, R. (1968) ‘The death of the author’, reprinted in Image, Music, Text. London: HarperCollins: 142-148.
27. Barton, J.H. (1991) ‘Patenting life’. Scientific American264(3): 40-46.
28. Basalla, G. (1988)The Evolution of Technology. Cambridge: Cambridge University Press.
29. Beer, J.J. (1958) ‘Coal tar dye manufacture and the origins of the modern industrial research laboratory’. ISIS49(2): 123-131.
30. Beier, F.-K. (1986) ‘The inventive step in its historical development’. International Review of Industrial Property and Copyright Law17: 301.
31. Bensaude-Vincent, B. and I. Stengers (1996) A History of Chemistry.Cambridge and London: Harvard University Press.
32. Bent, S.A., R.L. Schwaab, D.G. Conlin and D.D. Jeffery (1987)Intellectual Property Rights in Biotechnology Worldwide.Basingstoke: Macmillan.
33. Bercovitz-Rodriguez, A. (1990) ‘Historical trends in protection of technology in developed countries and their relevance for developing countries’. Geneva: United Nations Conference on Trade and Development.
34. Bessen, J. and M.J. Meurer (2008)Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk.Princeton: Princeton University Press.
35. Bhagwati, J. (1998) A Stream of Windows: Unsettling Reflections on Trade, Immigration and Democracy.Cambridge: MIT Press.
36. Bijman, J. (1999) ‘Life science companies: Can they combine seeds, agrochemicals and pharmaceuticals?’Biotechnology and Development Monitor40: 14-19.
37. Birch, A. (1992) ‘Steroid hormones and the Luftwaffe. A venture into fundamental strategic research and some of its consequences: The Birch reduction becomes a birth reduction’. Steroids 57: 363-377.
38. Black, J.W., W.A.M. Duncan, C.J. Durant, C.R. Ganellin and E.M. Parsons (1972) ‘Definition and antagonism of histamine H2-receptors’. Nature236: 385-390.
39. Blakeney, M. (2004) ‘Commentary’, in A. Ilardi and M. Blakeney (Eds.), International Encyclopaedia of Intellectual Property Treaties.Oxford: Oxford University Press.
40. Bliss, M. (1982)The Discovery of Insulin. Toronto: McLelland and Stewart.
41. Boldrin, M. and D.K. Levine (2004) ‘The case against intellectual monopoly’. International Economic Review45: 327-350.
42. Bonnett, R., J.R. Cannon, A.W. Johnson, I. Sutherland, A.R. Todd and E.L. Smith (1955) ‘The structure of B12 and its hexacarboxylic acid degradation product’. Nature176: 328-330.
43. Borson, D.B. (1995) ‘The Human Genome Project: Patenting human genes and biotechnology. Is the human genome patentable?’IDEA-The Journal of Law and Technology35(4): 461-496.
44. Boyle, J. (1996)Shamans, Software and Spleens: Law and the Social Construction of the Information Economy.Cambridge: Harvard University Press.
45. Bozicevic, K. (1987) ‘Distinguishing “products of nature” from products derived from nature’. Journal of the Patent and Trademark Office Society69(8): 415-426.
46. Bradsher, K. (2001) ‘Bayer agrees to charge government a lower price for anthrax medicine’. New York Times 25 October.
47. Braithwaite, J. (1984)Corporate Crime in the Pharmaceutical Industry.London: Routledge and Kegan Paul.
48. Braithwaite, J. and P Drahos (2000)Global Business Regulation.Cambridge: Cambridge University Press.
49. Breedveld, F.C. (2000) ‘Therapeutic monoclonal antibodies’. The Lancet355: 735-740.
50. Bristol-Myers Squibb (2001) ‘Annual Report, 2000’.
51. Brotzu, G. (1948) ‘Richerche su di un nuovo antibiotico’. Lavori dell’Istituto d’Igiene di Cagliari: 4-18. Downloadable from http://pacs.unica.it/brotzu/brotzu.pdf. English translation:http://pacs.unica.it/brotzu/brotzuen.pdf.
52. Brown, K. (2004)Penicillin Man: Alexander Fleming and the Antibiotic Revolution. Stroud: Sutton.
53. Brown, P. and K. Kleiner (1994) ‘Patent row splits breast cancer researchers’. New Scientist143: 4.
54. Bud, R. (1993)The Uses of Life: A History of Biotechnology.Cambridge: Cambridge University Press.
55. Bud, R. (2007)Penicillin: Triumph and Tragedy.Oxford: Oxford University Press.
56. Bud, R. (2008) ‘Upheaval in the moral economy of science? Patenting, teamwork and the World War II experience of penicillin’. History and Technology24 (2): 173-190.
57. Buttel, F.H. and J. Belsky (1987) ‘Biotechnology, plant breeding, and intellectual property: Social and ethical dimensions’. Science, Technology, and Human Values12(1): 31-49.
58. Bynum, W.E. (1994)Science and the Practice of Medicine in the Nineteenth Century. Cambridge: Cambridge University Press.
59. Calvert, J. (2004) ‘Genomic patenting and the utility requirement’. New Genetics and Society 23(3): 301-312.
60. Calvert, J. and P.-B. Joly (2008) ‘The ontology of the gene and the patenting of DNA: How did the gene become a chemical compound?’ Unpublished paper on file with author.
61. Carvalho, N. (2004) ‘The problem of gene patents’. Washington University Global Studies Law Review3(3): 701-753.
62. Cassier, M. and C. Sinding (2008) “‘Patenting in the public interest”: Administration of insulin patents by University of Toronto’. History and Technology24(2): 153-171.
63. Cello, J., A.V. Paul and E. Wimmer (2002) ‘Chemical synthesis of poliovirus cDNA: Generation of infectious virus in the absence of natural template’. Science297: 1016-1018.
64. Chain, E., H.W. Florey, A.D. Gardner, N.G. Heatley, M.A. Jennings, J. Orr-Ewing and A.G. Sanders (1940) ‘Penicillin as a chemotherapeutic agent’. The LancetAugust 24: 226-228.
65. Chandler A.D. (1990)Scale and Scope: The Dynamics of Industrial Capitalism. Cambridge and London: Belknap Press.
66. Chartered Institute of Patent Agents (CIPA) (1998) ‘Briefing paper-Patenting in the pharmaceutical industry-Supplementary Protection Certificates’. London: CIPA.
67. Chung, Y., I. Klimanskaya, S. Becker, T. Li, M. Maserati, S.-J. Lu, T. Zdravkovic, D. Ilic, O. Genbacev, S. Fisher, A. Krtolica and R. Lanza (2008) ‘Human embryonic stem cell lines generated without embryo destruction’. Cell Stem Cell2: 113-117.
68. Church, R. and E.M. Tansey (2007)Burroughs Wellcome & Co.: Knowledge, Trust, Profit and the Transformation of the British Pharmaceutical Industry, 1880-1940. Lancaster: Crucible Books.
69. Cloatre, E. (2006) ‘From international ethics to European Union policy: A case study on biopiracy in the EU’s Biotechnology Directive’. Law and Policy 28(3): 345-367.
70. Coghlan, A. (1994) ‘Applications for gene patents “thrown on bonfire”’. New Scientist 19 February: 4-5.
71. Colton, F. (1992) ‘Steroids and “the pill”: Early steroid research at Searle’. Steroids57: 624-630.
72. Commission on Intellectual Property Rights (1997)Towards the Era of Intellectual Creation: Challenges for Breakthrough. The Report of the Commission on Intellectual Property Rights in the Twenty-first Century.Tokyo: JPO.
73. Commons, J.R. (1934)Institutional Economics: Its Place in Political Economy. New York: Macmillan.
74. Consumer Project on Technology, Essential Action, Oxfam, Treatment Access Campaign and Health Gap (2001) ‘Comment on the Attaran/Gillespie-White and PhRMA surveys of patents on antiretroviral drugs in Africa’.
75. Cook-Deegan, R. (1994)The Gene Wars: Science, Politics, and the Human Genome. New York: W.W. Norton.
76. Cook-Deegan, R. and S.J. McCormack (2001) ‘Patents, secrecy, and DNA’. Science293: 217.
77. Cookson, C. (2001) ‘UK scientists responsible for third of genome project’. Financial Times, 13 February: 2.
78. Coombe, R.J. (1998)Cultural Life of Intellectual Properties: Authorship, Appropriation, and the Law.Durham: Duke University Press.
79. Cooper, M.H. (1966)Prices and Profits in the Pharmaceutical Industry.Oxford and London: Pergamon Press.
80. Cornforth, J.W. (1993) ‘The trouble with synthesis’. Australian Journal of Chemistry46: 157-170.
81. Cornish, W.R. (1999)Intellectual Property: Patents, Copyright, Trade Marks and Allied Rights (fourth edition). London: Sweet and Maxwell.
82. Correa, C.M. (2001)Trends in Drug Patenting: Case Studies.Buenos Aires: Corregidor.
83. Correa, C.M. (2004) ‘Bilateralism in intellectual property: Defeating the WTO system for access to medicines’. Case Western Reserve Journal of International Law36: 79.
84. Correa, C.M. (2006) ‘Protecting test data for pharmaceutical and agrochemical products under free trade agreements’, in P. Roffe, G. Tansey and D. Vivas-Eugui (Eds.), NegotiatingHealth: Intellectual Property and Access to Medicines.London: Earthscan.
85. Couzin, J. (2002) ‘Active poliovirus baked from scratch’. Science297: 174-175.
86. Cragg, G.M., D.J. Newman and K.M. Snader (1997) ‘Natural products in drug discovery and development’. Journal of Natural Products60(1): 52-60.
87. CRA International (2008) ‘The current state of innovation in the pharmaceutical industry’. London: CRA International.
88. Crick, F. (1958) ‘On protein synthesis’. Symposium of the Society of Experimental Biology12: 138-163.
89. Csete, M.E. and J.C. Doyle (2002) ‘Reverse engineering of biological complexity’. Science295: 1664-1669.
90. Darden, L. (2006) ‘Anomoly identification and resolution for the central dogma of molecular biology’, in Max Planck-Institut für Wissenschaftsgeschichte, History and Epistemology of Molecular Biology and Beyond: Problems and Perspectives (Preprint 310). Berlin: MPIWG, 127-139.
91. Davies, K. (2001)The Sequence: Inside the Race for the Human Genome.London: Weidenfeld and Nicolson.
92. Davies, P. (2003)The Origin of Life.London: Penguin.
93. Dawkins, R. (2004)The Ancestor’s Tale: A Pilgrimage to the Dawn of Life.London: Weidenfeld and Nicolson.
94. Dewar, E. (2004)The Second Tree: Stem Cells, Clones, Chimeras, and Quests for Immortality.New York: Carroll and Graf.
95. Dickenson, D. (2008)Body Shopping: The Economy Fuelled by Flesh and Blood. Oxford: Oneworld.
96. DiMasi, J.A. and H.G. Grabowski (2007) ‘The cost of biopharmaceutical R&D: Is biotech different?’Managerial and Decision Economics28: 469-479.
97. Djerassi, C. (1984) ‘A steroid autobiography’. Steroids43(4): 351-361.
98. Djerassi, C. (2001)The Man’s Pill: Reflections on the 50th Birthday of the Pill.Oxford: Oxford University Press.
99. Djerassi, C., L. Miramontes, G. Rosenkranz and F. Sondheimer (1954) ‘Synthesis of 19-nor-17a-ethynyltestosterone and 19-nor-17a-methytestosterone’. Journal of the American Chemical Society76: 4092-4094.
100. Doern, G.B. (1999)Global Change and Intellectual Property Agencies.London and New York: Pinter.
101. Doll, J. (1998) ‘Biotechnology: The patenting of DNA’. Science280: 689-690.
102. Dormandy, T. (2006)The Worst of Evils: The Fight Against Pain.New Haven and London: Yale University Press.
103. Drahos, P. (1995) ‘Global property rights in information: The story of TRIPS at the GATT’. Prometheus13(1): 6-19.
104. Drahos, P. (1997) ‘States and intellectual property: The past, the present and the future’, in D. Saunders and B. Sherman (Eds.), From Berne to Geneva: Recent Developments in Copyright and Neighbouring Rights.Brisbane: Australian Key Centre for Cultural and Media Policy and Impart Corporation.
105. Drahos, P. (1999a) ‘Biotechnology patents, markets and morality’. European Intellectual Property Review21(9): 441-449.
106. Drahos, P. (1999b) ‘Designing institutions in the information society’, in S. Macdonald and J. Nightingale (Eds.), Information and Organization: A Tribute to the Work of Don Lamberton.Amsterdam: Elsevier Science.
107. Drug and Market Development (1998) ‘Monoclonal antibody therapy for leukemia and lymphoma’. Drug and Market Development9(100): 264.
108. D’Silva, J.E. (1989) ‘Patenting of animals: A welfare viewpoint’, in International Coalition for Development Action, Patenting Life Forms in Europe. Proceedings of an International Conference at the European Parliament, Brussels, 7-8 February 1989.Barcelona: ICDA Seeds Campaign.
109. Duffin, J. (1999)History of Medicine: A Scandalously Short Introduction.Toronto: University of Toronto Press.
110. Dutfield, G. (2005) ‘Thinking aloud about disclosure of origin’. QUNO Occasional Paper 18, Geneva: Quaker United Nations Office.
111. Dutfield, G. (2006a) “‘To copy is to steal”: TRIPS, (un)free trade agreements & thenew intellectual property fundamentalism’. Journal of Information, Law & Technology1.
112. Dutfield, G. (2006b) ‘Protecting traditional knowledge: pathways to the future’. International Centre for Trade and Sustainable Development.Issue Paper 16.
113. Dutfield, G. (2008) ‘Knowledge diplomacy and the new intellectual property fundamentalism’, in J. Malbon and C. Lawson (Eds.), Interpreting and Implementing the TRIPS Agreement: Is it Fair? Cheltenham: Edward Elgar.
114. Dutfield, G. and U. Suthersanen (2005) ‘Harmonisation or differentiation in intellectual property protection? The lessons of history’. Prometheus23 (2): 131-147.
115. Dutton, H.I. (1984)The Patent System and Inventive Activity during the Industrial Revolution,1750-1852. Manchester: Manchester University Press.
116. Dyer, G. (2002) ‘Seeking freedom in New England’. Financial Times 8 May: 13.
117. Economist Intelligence Unit (2005) ‘Targeted treatments and the prospects for pharmaceuticals’. London, New York and Hong Kong: EIU.
118. Eggertsson, T. (1990)Economic Behaviour and Institutions.Cambridge: Cambridge University Press.
119. Engelberg, A.B. (1999) ‘Special patent provisions for pharmaceuticals: Have they outlived their usefulness? A political, legislative and legal history of US law and observations for the future’. IDEA-The Journal of Law and Technology 39(3): 389-425.
120. Enyart, J.R. (1990) ‘A GATT intellectual property code’. Les Nouvelles June: 53-56.
121. Ernhofer, K. (2003) ‘Who really owns your genes?’Christian Science Monitor27 February.
122. ETC Group (2001) ‘Globalization, Inc. concentration in corporate power: The unmentioned agenda’. ETC Group Communiqué (71).
123. ETC Group (2007) ‘Extreme genetic engineering: An introduction to synthetic biology’. Ottawa: ETC Group.
124. European Commission-Directorate-General for Research (2007) ‘Synthetic Biology: A NEST Pathfinder initiative’. Brussels: European Commission.
125. European Federation of Pharmaceutical Industries and Associations (EFPIA) (1998) ‘The pharmaceutical industry in figures. 1998 edition’. Brussels: EFPIA.
126. European Federation of Pharmaceutical Industries and Associations(1999) ‘Position paper-WTO Millennium Round’. Brussels: EFPIA.
127. European Federation of Pharmaceutical Industries and Associations(2008) ‘The pharmaceutical industries in figures. 2008 edition’. Brussels: EFPIA.
128. European Patent Office (2007) Scenarios for the Future: How Might IP Regimes Evolve by 2025? What Global Legitimacy Might Such Regimes Have? Munich: EPO.
129. Ezzell, C. (2002) ‘Proteins rule’. Scientific American286(4): 26-33.
130. Farrar, W.V. (1974) ‘Synthetic dyes before 1860’. Endeavour33: 149-155.
131. Ferguson, N. (1997) ‘Introduction’, in N. Ferguson (Ed.), Virtual History: Alternatives and Counterfactuals.London: Picador.
132. Ferreira, S.H., S. Moncadaand J.R. Vane (1971) ‘Indomethacin and aspirin abolish prostaglandin release from the spleen’. Nature New Biology231: 237-239.
133. Fishbein, M. (1937a) ‘Are patents on medicinal discoveries and on foods in the public interest?’Journal of the Patent Office Society19(12): 891-904.
134. Fishbein, M. (1937b) ‘Medical patents’. Journal of the American Medical Association109(19): 1539-1543.
135. Fleming, A. (1929) ‘On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. Influenzae’. British Journal of Experimental PathologyX(3): 226-236.
136. Food and Agriculture Organization of the United Nations (FAO) (1993) ‘Convention on Biological Diversity and related resolutions’. Commission on Plant Genetic Resources, Fifth session, Rome, 19-23 April 1993 (CPGR/93/Inf.3).
137. Fore J., I.R. Wiechersand, R. Cook-Deegan (2006) ‘The effects of business practices, licensing, and intellectual property on development and dissemination of the polymerase chain reaction: Case study’. Journal of Biomedical Discovery and Collaboration1(7): 1-17.
138. Foucault, M. (1979) ‘What is an author?’ in Hariri, J.V. (Ed.), Textual Strategies: Perspectives in Post-Structuralist Criticism.Ithaca: Cornel University Press.
139. Fowler, C. (1994)Unnatural Selection: Technology, Politics, and Plant Evolution. Yverdon: Gordon and Breach.
140. Fransman, M. and S. Tanaka (1999) ‘Visions of future technologies: Government, globalisation, and universities in Japanese biotechnology’, in M. Fransman (Ed.), Visions of Innovation: The Firm and Japan.Oxford: Oxford University Press.
141. Frederickson, D.S. (2001)The Recombinant DNA Controversy: A Memoir-Science, Politics, and the Public Interest 1974-1981.Washington DC: ASM Press.
142. Freeman, C. and L. Soete. (1997)The Economics of Industrial Innovation.London: Pinter.
143. Freudenheim, M. (1994) ‘New drug era begins as Tagamet patent expires’. New York Times 17 May.
144. Frost, G.E. (1963) ‘The case against drug patent compulsory licensing’. The Patent, Trademark and Copyright Journal of Research and Education7(1): 84-102.
145. Fukuyama, F. (2002)Our Postmodern Future: Consequences of the Biotechnology Revolution. New York: Farrar, Straus and Giroux.
146. Galambos, L., with J.E. Sewell (1995)Networks of Innovation: Vaccine Development at Merck, Sharp & Dohme, and Mulford, 1895-1995.New York: Cambridge University Press.
147. Gamow, G. (1955) ‘Information transfer in the living cell’. Scientific American193: 70-78.
148. Garfield, S. (2001)Mauve: How One Man Invented a Colour that Changed the World. London: Faber.
149. Gaudilliere, J.-P. (2008) ‘Professional or industrial order? Patents, biological drugs, and pharmaceutical capitalism in early twentieth century Germany’. History and Technology24(2): 107-133.
150. Gervais, D. (1998)The TRIPS Agreement: A Negotiating History.London: Sweet and Maxwell.
151. Gibbs, W.W. (2003) ‘The unseen genome: Gems among the junk’. Scientific American289(5): 26-33.
152. Gilbert, D., T. Walley and D. New (2000) ‘Lifestyle medicines’. British Medical Journal1321: 1341-1344.
153. Gispen, K. (1989)New Profession, Old Order: Engineers and German Society, 1815-1914.Cambridge: Cambridge University Press.
154. Glyn, J. (1998) ‘The discovery and early use of cortisone’. Journal of the Royal Society of Medicine91(10): 513-517.
155. Gold, E.R. and J. Carbone (2008) ‘Myriad: In the eye of the policy storm’. Montreal: The Innovation Partnership and McGill University Centre for Intellectual Property Policy.
156. Goldstein, D.B. and G.L. Cavalleri (2005) ‘Understanding human diversity’. Nature437: 1241-1242.
157. Goodman, J. (2003) ‘Pharmaceutical industry’, in R. Cooter and J. Pickstone (Eds.), Companion to Medicine in the Twentieth Century.London: Routledge.
158. Goodman, J. and V. Walsh (2001)The Story ofTaxol: Nature and Politics in the Pursuit of an Anti-cancer Drug.Cambridge: Cambridge University Press.
159. Goozner, M. (2004)The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkeley, Los Angeles and London: University of California Press.
160. Gould, S.J. (2000) ‘More things in heaven and earth’, in H. Rose and S. Rose (Eds.), Alas, PoorDarwin: Arguments Against Evolutionary Psychology.London: Jonathan Cape.
161. Graff, G. (2002) ‘The sources of biological innovation for agriculture’ (PhD thesis). Department of Agricultural and Resource Economics, University of California, Berkeley.
162. Granstrand, O. (1999)The Economics and Management of Intellectual Property: Towards Intellectual Capitalism.Cheltenham and Northampton: Edward Elgar.
163. Green, A.G. (1915 [1901]) ‘The relative progress ofthe coal-tar colour industry in England and Germany during the past fifteen years’, in W.M. Gardner (Ed.), The British Coal-Tar Industry: Its Origin, Development and Decline.London: Williams and Norgate.
164. Greenberg, A.S. (1926) ‘The lesson of the German-owned US chemical patents’. Journal ofthe Patent Office Society9(1): 19-35.
165. Griffiths, P.E. and K. Stotz (2007) ‘Gene’, in D.L. Hull and M. Ruse (Eds.), The Cambridge Companion to the Philosophy of Biology.New York: Cambridge University Press.
166. Groves, P., A. Martino, C. Miskin and J. Richards (1993)Intellectual Property and the Internal Market of the European Community.London, Dordrecht, Boston: Graham and Trotman.
167. Grubb, P.W. (1999)Patents for Chemicals, Pharmaceuticals and Biotechnology. Oxford: Clarendon Press.
168. Grubb, P.W. (2003) ‘A patently negative view of industry’. Nature Biotechnology21(12): 1439-1440.
169. The Guardian (various authors) (2000) ‘Patenting life-Special report’ (special supplement). The Guardian15 November.
170. Haber, L.F. (1958)The Chemical Industry during the Nineteenth Century: A Study of the Economic Aspect of Applied Chemistry in Europe and North America.Oxford: Clarendon Press.
171. Hale, C.W., G.G.F. Newton and E.P. Abraham (1961) ‘Derivatives of cephalosporin C formed with certain heterocyclic tertiary bases’. Biochemical Journal79: 403-408.
172. Hale, R.J. (1923) ‘Coercion and distribution in a supposedly non-coercive state’. Political Science Quarterly38(3): 470-494.
173. Hall, J.M., M.K. Lee, B. Newman, J.E. Morrow, L.A. Anderson, B. Huey and M.C. King (1990) ‘Linkage of early-onset familial breast cancer to chromosome 17q21’. Science 250: 1684-1649.
174. Hall, S.S. (1987)Invisible Frontiers: The Race to Synthesize a Human Gene. New York: Atlantic Monthly Press.
175. Hancher, L. (1990)Regulating for Competition: Government, Law, and the Pharmaceutical Industry in the United Kingdom and France.Oxford: Clarendon Press.
176. Hancher, L. and M. Moran (1998) ‘Organizing regulatory space’, in R. Baldwin, C. Scott and C. Hood (Eds.), A Reader on Regulation.Oxford: Oxford University Press.
177. Hara, T. (2003)Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development.Cheltenham: Edward Elgar.
178. Hare, R. (1970)The Birth of Penicillin.London: Allen and Unwin.
179. Harrison, B. (1997)Lean and Mean: The Changing Landscape of Corporate Power in the Age of Flexibility.New York and London: Guilford Press.
180. Haynes, W. (1945)American Chemical Industry. Volume 2, The World War Period: 1912-22.New York: Van Nostrand.
181. Heinemann, M. and S. Panke (2006) ‘Synthetic biology-Putting engineering into biology’. Bioinformatics22: 2790-2799.
182. Heller, M.A. and R.S. Eisenberg (1998) ‘Can patents deter innovation? The anticommons in biomedical research’. Science280: 698-701.
183. Hendrickx, F., V Koester and C. Prip (1993) ‘Access to genetic resources: A legal analysis’. Environmental Policy and Law23 (6): 250-258.
184. Henley, J. (2001) ‘Cancer unit fights US gene patent’. The Guardian8 September.
185. Henry, C., M. Trommetter and L. Tubiana (2003) ‘Innovations et droits de propriété intellectuelle: Quells enjeux pour les biotechnologies?’ Paris: Rapport du Conseil d’Analyse Economique.La Documentation Française:49-112.
186. Herzog, H. and E.P. Oliveto (1992) ‘A history of significant steroid discoveries and developments originating at the Schering Corporation (USA) since 1948’. Steroids57: 617-623.
187. Heusler, K. and Kalvoda J. (1992) ‘Between basic and applied research: Ciba’s involvement in the steroids in the 1950s and 1960s. Steroids61: 492-503.
188. Hirschmann, R. (1992) ‘The cortisone era: Aspects of its impact. Some contributions of the Merck Laboratories. Steroids57: 579-592.
189. Hoare, A.L. and R.G. Tarasofsky (2006) ‘Disclosure of origin in IPR applications: Options and perspectives of users and providers of genetic resources’. A Chatham House report prepared for the project Impacts of the IPR Rules on Sustainable Development (IPDEV), funded by the European Commission under its 6th Framework Programme. London: Royal Institute of International Affairs.
190. Hoare, A.L. and R.G. Tarasofsky (2007) ‘Asking and telling: Can “disclosure of origin” requirements in patent applications make a difference?’Journal of World Intellectual Property10(2): 149-169.
191. Hodgkin, D.C. and E.N. Maslen (1961) ‘The X-ray analysis of the structure of cephalosporin C’. Biochemical Journal79: 393-402.
192. Hodgkin, D.C. and E.N. Maslen, J. Pickworth, J.H. Robertson, K.N. Trueblood, R.J. Prosen and J.G. White (1955) ‘The crystal structure of the hexacarboxylic acid derived from B12 and the molecular structure of the vitamin’. Nature176: 325-328.
193. Hogg, J.A. (1992) ‘Steroids, the steroid community, and Upjohn in perspective: a profile of innovation’. Steroids57: 593-616.
194. Homburg, E. (1992) ‘The emergence of research laboratories in the dyestuffs industry, 1870-1900’. British Journal for the History of Science25: 91-111.
195. Hope, J. (2008)Biobazaar: The Open Source Revolution.Cambridge and London: Harvard University Press.
196. Hornix, WJ. (1992) ‘From process to plant: Innovation in the early artificial dye industry’. British Journal for the History of Science25: 65-90.
197. Horstmeyer, M. (1998) ‘The industry evolves within a political, social, and public policy context: A brief look at Britain, Germany, Japan, and the United States’, in A. Arora, R. Landau and N. Rosenberg (Eds.), Chemicals and Long-term Economic Growth: Insights from the Chemical Industry.New York, Chichester, Weinheim, Brisbane, Singapore and Toronto: John Wiley.
198. Howells, J. and I. Neary (1995)Intervention and Technological Innovation: Government and the Pharmaceutical Industry in the UK and Japan.Basingstoke and London: Macmillan.
199. Howlett, M.J. and A.F. Christie (2004) ‘An analysis of the approach of the European, Japanese and United States patent offices to patenting partial DNA sequences (ESTs)’. University of Melbourne Faculty of Law Legal Studies Research Paper 82.
200. Hughes, S.S. (2001) ‘Making dollars out of DNA: The first major patent in biotechnology and the commercialization of molecular biology, 1974-1980’. ISIS92(3): 541-575.
201. Hunt, M. (2002)Changing Patterns of Pharmaceutical Innovation.Washington DC: National Institute of Health Care Management Research and Educational Foundation.
202. Hunter, G.K. (2000)Vital Forces: The Discovery of the Molecular Basis of Life. London and San Diego: Academic Press.
203. International Expert Group on Biotechnology, Innovation and Intellectual Property of the Innovation Partnership (2008) ‘Toward a new era of intellectual property: from confrontation to negotiation’. Montreal: The Innovation Partnership and McGill University Centre for Intellectual Property Policy.
204. International HapMap Consortium (2005) ‘A haplotype map of the human genome’. Nature437: 1299-1320.
205. International Human Genome Sequencing Consortium (2001) ‘Initial sequencing and analysis of the human genome’. Nature409: 860-921.
206. Jackson, J.H. (1997)The World Trading System: Law and Policy of International Economic Relations (Second edition). Cambridge and London: The MIT Press.
207. Jaffe, A.B. and J. Lerner (2004)Innovation and its Discontents: How our Broken Patent System is Endangering Innovation and Progress, and What to do About it. Princeton: Princeton University Press.
208. Japan Patent Office (2000)Examination Guidelines for Patent and Utility Model. Tokyo: JPO.
209. Jaszi, P. (1992) ‘On the author effect: Contemporary copyright and collective creativity’. Cardozo Arts and Entertainment Law Journal10(2): 293-320.
210. Jeffreys, D. (2004)Aspirin: The Story of a Wonder Drug.London: Bloomsbury.
211. Johnson, C. (1995)Japan: Who Governs? The Rise of the Developmental State. New York and London: W.W. Norton and Company.
212. Johnson, J.A. (1992) ‘Hofmann’s role in reshaping the academic-industrial alliance in German chemistry’, in C. Meinel and H. Scholz (Eds.), Die Allianz von Wissenschaft und Industrie August Wilhelm Hofmann (1818-1892). Weinheim, New York, Cambridge and Basel: VCH.
213. Joly, P.-B. (1999) ‘Introduction: Innovations and networks in biotechnology’. International Journal of Biotechnology1(1): 1-9.
214. Jones, E. (2001) The Business of Medicine: The Extraordinary History of Glaxo, aBaby Food Producer, Which Became One of the World’s Most Successful Pharmaceutical Companies. London: Profile Books.
215. Journal of the American Medical Association (editorial) (1937) ‘Deaths following Elixir of Sulfanilamide-Massengill’. Journal of the American Medical Association109(19): 1544-1545.
216. Judson, H.F. (1996)The Eighth Day of Creation: Makers of the Revolution in Biology (expanded edition). Plainview: Cold Spring Harbor Laboratory Press.
217. Kaitin, K.I. (2000) ‘Don’t turn back the clock on drug regulatory reform’. Boston: Tufts Center for the Study of Drug Development.
218. Kaufer, E. (1980)The Economics of the Patent System.Chur: Harwood Academic Publishers.
219. Kay, L.E. (1993)The Molecular Vision of Life: Caltech, the Rockefeller Foundation, and the Rise of the New Biology.New York and Oxford: Oxford University Press.
220. Kay, L.E. (2000)Who Wrote the Book of Life? A History of the Genetic Code.Stanford: Stanford University Press.
221. Kefauver, E., I. Till (1966) In a Few Hands: Monopoly Power in America. Harmondsworth: Penguin Books.
222. Kell, D. (1992) ‘The furore over the patenting of animals: Animal Legal Defense Fund v. Quigg’. European Intellectual Property Review14(8): 279-283.
223. Kendall, E.C. (1971)Cortisone.New York: Charles Scribner’s Sons.
224. Kenney, M. (1986)Biotechnology: The University-Industrial Complex.New Haven: Yale University Press.
225. Kevles, D.J. (1994) ‘Ananda Chakrabarty wins a patent: Biotechnology, law, and society, 1972-1980’. Historical Studies in the Physical and Biological Sciences25(1): 111-135.
226. Kevles, D.J. (2001) ‘Patenting life: A historical overview of law, interests, and ethics’. Prepared for the Legal Theory Workshop, Yale Law School, 20 December.
227. Kevles, D.J. (2006) ‘Breeding, biotechnology, and agriculture: The establishment and protection of intellectual property in animals since the late eighteenth century’, in Max Planck-Institut für Wissenschaftsgeschichte, History and Epistemology of Molecular Biology and Beyond: Problems and Perspectives(Preprint 310). Berlin: MPIWG, 69-79.
228. Kingston, W (2004a) ‘Streptomycin, Schatz v. Waksman, and the balance of credit for discovery’. Journal of the History of Medicine and Allied Sciences59(3): 441-462.
229. Kingston, W (2004b) ‘Removing some harm from the World Trade Organization’. Oxford Development Studies32(2): 309-320.
230. Kintisch, E. (2005) ‘Court tightens patent rules on gene tags’. Science309: 1797.
231. Kitano, H. (2008) ‘Synthetic biology: A brief overview’. Science295: 1662-1664.
232. Klauer, G. (1936) ‘The new German patent law’. Journal of the Patent Office Society18(8): 481-500.
233. Kleiner, K. (2002) ‘Bad for your health: Are gene patents stopping patients getting the latest tests?’New Scientist 23 March: 6.
234. Kobrak, C. (2002)National Cultures and International Competition: The Experience of Schering AG, 1851-1950.Cambridge: Cambridge University Press.
235. Köhler, G. and C. Milstein (1975) ‘Continuous cultures of fused cells secreting antibody of predefined specificity’. Nature256: 495-497.
236. Kornberg, A. (1995)The Golden Helix: Inside Biotech Ventures.Sausalito: University Science Books.
237. Kresge, N., R.D. Simoni and R.L. Hill (2005) ‘Hemorrhagic sweet clover disease, dicumarol, and warfarin: The work of Karl Paul Link’. Journal of Biological Chemistry280(8): e5-e6.
238. Krimsky, S. (2000) ‘Risk assessment and regulation of bioengineered food products’. International Journal of Biotechnology2 (1/2/3): 231-238.
239. Krimsky, S. (2003) Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? Lanham: Rowman & Littlefield.
240. Kronstein, H. and I. Till (1947) ‘A reevaluation of the international patent convention’. Law and Contemporary Problems12: 765-781.
241. Lane, J.E. (1995)The Public Sector: Concepts, Models and Approaches (Second edition). London, Newbury Park and New Delhi: Sage Publications.
242. Lange, P. (1997), ‘The non-patentability of plant varieties. The Decision of the Technical Board of Appeal 3.3.4 of February 21, 1995-T 356/93’. PlantVariety Protection83: 25-33.
243. Last, J. (2002) ‘The missing Link: The story of Karl Paul Link’. Toxicological Sciences66: 4-6.
244. Laveaga, G.S. (2005) ‘Uncommon trajectories: Steroid hormones, Mexican peasants, and the search for a wild yam’. Studies in History and Philosophy of Biological and Biomedical Sciences36: 743-760.
245. Law, J. (2006)Big Pharma: How the World’s Biggest Drug Companies Control Illness. London: Constable.
246. Lawrence, S. and P. Treacy (2005) ‘The Commission’s AstraZeneca decision: Delaying generic entry is an abuse of a dominant position’. Journal of Intellectual Property Law and Practice1 (1): 7-9.
247. Lax, E. (2004)The Mould in Dr Florey’s Coat: The Remarkable True Story of the Penicillin Miracle.London: Little, Brown.
248. Lazell, H.G. (1975)From Pills to Penicillin: The Beecham Story.London: Heinemann.
249. Lear, J. (1978)Recombinant DNA: The Untold Story.New York: Crown Publishers.
250. Le Fanu, J. (1999)The Rise and Fall of Modern Medicine. London: Little, Brown and Co.
251. Lesch, J.E. (2007)The First Miracle Drugs: How the Sulpha Drugs Transformed Medicine.New York: Oxford University Press.
252. Levin, R.C., A.K. Klevorick, R.R. Nelson and S.G. Winter (1987) ‘Appropriating the returns from industrial research and development’. Brookings Papers on Economic Activity: 783-820.
253. Liebenau, J. (1984) ‘Industrial R&D in pharmaceutical firms in the twentieth century’. Business History26(3): 329-346.
254. Link, K.P. (1959) ‘The discovery of Dicumarol and its sequels’. Circulation19: 97-107.
255. Litman, J. (2001)Digital Copyright.Amherst: Prometheus Books.
256. Lloyd, M. (2002) ‘Philip Showalter Hench, 1896-1965’. Rheumatology41: 582-584.
257. Loder, B., G.G.F. Newton and E.P. Abraham (1961) ‘The cephalosporin C nucleus (7-aminocephalosporanic acid) and some of its derivatives’. Biochemical Journal79: 408-416.
258. Lok, L. (2002) ‘Software for signaling networks, electronic and cellular’. Science’s STKE122: PE11.
259. Macdonald, S. (2001) ‘Exploring the hidden costs of patents’. QUNO Occasional Paper 4. Geneva: Quaker United Nations Office.
260. Macfarlane, G. (1979)Howard Florey: The Making of a Great Scientist.Oxford: Oxford University Press.
261. Macfarlane, G. (1984)Alexander Fleming: The Man and the Myth.Cambridge: Harvard University Press.
262. Machlup, F. and E. Penrose (1950) ‘The patent controversy in the Nineteenth Century’. Journal of Economic History10(1): 1-29.
263. Maclagan, T. (1876) ‘The treatment of acute rheumatism by salicin’. The Lancet4 March 1876, 342-343.
264. MacLeod, C. (1988)Inventing the Industrial Revolution: The English Patent System, 1660-1800.Cambridge: Cambridge University Press.
265. Majone, G. (1996)Regulating Europe.London and New York: Routledge.
266. Makkai, T. and J. Braithwaite (1998) ‘In and out of the revolving door: Making sense of regulatory capture’, in R. Baldwin, C. Scott and C. Hood (Eds.), A Reader on Regulation. Oxford: Oxford University Press.
267. Mann, J. (1999)The Elusive Magic Bullet: The Search for the Perfect Drug.Oxford: Oxford University Press.
268. Mann, C.C. and M.L. Plummer (1991)The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Competition.Cambridge: Harvard Business School Publications.
269. Manners, S. (2006)Super Pills: The Prescription Drugs We Love to Take.Vancouver: Raincoast Books.
270. Mansfield, E. (1986) ‘Patents and innovation: An empirical study’. Management Science32(2): 173-181.
271. March, J.G. and J.P. Olson (1984) ‘The new institutionalism: Organizational factors in political life’. American Political Science Review78: 738-749.
272. Margulis, L. and D. Sagan (1987)Microcosmos: Four Billion Years of Microbial Evolution.London: Allen and Unwin.
273. Marks, L.V. (2001)Sexual Chemistry: A History of the Contraceptive Pill. New Haven: Yale University Press.
274. Matthews, D. (2002)Globalising Intellectual Property Rights: The TRIPS Agreement. London: Routledge.
275. Mattick, J.S. (2004) ‘The hidden genetic program of complex organisms’. Scientific American291(4): 30-37.
276. May, C. (2007)The World Intellectual Property Organization: Resurgence and the Development Agenda.London: Routledge.
277. May, C. and S. Sell (2006)Intellectual Property Rights: A Critical History.Boulder: Lynne Rienner Publishers.
278. McGrath, M. (1996) ‘The patent provisions in TRIPS: Protecting reasonable remuneration for services rendered-Or the latest development in Western colonialism?’European Intellectual Property Review18(7): 398-403.
279. McKelvey, M. (1996)Evolutionary Innovations: The Business of Biotechnology. Oxford: Oxford University Press.
280. Medawar, P. (1996)The Strange Case of the Spotted Mice and Other Classic Essays on Science. Oxford: Oxford University Press.
281. Médicins Sans Frontières (MSF) and Drugs for Neglected Diseases (DND) Working Group (2001) FatalImbalance: The Crisis in Research and Development for Drugs for Neglected Diseases.Geneva: MSF and DND Working Group.
282. Meek, J. (2000) ‘US firm may double cost of UK cancer checks’. The Guardian17 January.
283. Mercuro, N. and S.G. Medema (1997)Economics and the Law: From Posner to Post-modernism. Princeton: Princeton University Press.
284. Merges, R.P. (1996) ‘Contracting into liability rules: Intellectual property rights and collective rights organizations’. California Law Review84(5): 1293-1386.
285. Merges, R.P. (1997)Patent Law and Policy: Cases and Materials (Second edition). Charlottesville: Michie Law Publishers.
286. Merz, J.F., A.G. Kriss, D.G. Leonard and M.K. Cho (2002) ‘Diagnostic testing fails the test’. Nature415: 577-579.
287. Meyer-Thurow, G. (1982) ‘The industrialization of invention: A case study from the German chemical industry’. ISIS73: 363-381.
288. Milstein, C. (2000) ‘With the benefit of hindsight’. Immunology Today21(8): 359-364.
289. Miramontes, L., G. Rosenkranz and C. Djerassi (1951) ‘The synthesis of 19-norprogesterone’. Journal of the American Chemical Society73: 3540-3541.
290. Mirowski, P. (2007) ‘Johnny’s in the basement mixin’ up the medicine: Review of Angell, Avorn, and Daemmrich on the modern pharmaceutical predicament’. Social Studies of Science37 (2): 311-327.
291. Mooney, P.R. (1979) Seeds of the Earth: Private or Public Resource? Ottawa: Canadian Council for International Cooperation and International Coalition for Development Action.
292. Morange, M. (1998) A History of Molecular Biology.Cambridge: Harvard University Press.
293. Mowery, D.C. and N. Rosenberg (1998)Paths of Innovation: Technological Change in 20th Century America.Cambridge: Cambridge University Press.
294. Mowery, D.C., N. Rosenberg and B.N. Sampat (2001) ‘University patents and patent policy debates in the USA, 1925-1980’. Industrial and Corporate Change10(3): 781-814.
295. Moynihan, R. and D. Henry (2006) ‘The fight against disease mongering: Generating knowledge for action’. PLoS Medicine3 (4).
296. Moynihan, R. and A. Cassels (2005)Selling Sickness: How the World’s Biggest Pharmaceutical Companies are Turning us all into Patients.Vancouver: Greystone Books.
297. Mullis, K. (1990) ‘The unusual origins of the polymerase chain reaction’. Scientific American, April: 56-65.
298. Mundo, P.A. (1999)National Politics in a Global Economy: The Domestic Sources of US Trade Policy.Washington DC: Georgetown University Press.
299. Murmann, J.P. (2003)Knowledge and Competitive Advantage: The Coevolution of Firms, Technology and National Institutions.New York: Cambridge University Press.
300. Murmann, J.P. and R. Landau (1998) ‘On the making of competitive advantage: The development of the chemical industries of Britain and Germany since 1850’, in A. Arora, R. Landau and N. Rosenberg (Eds.), Chemicals and Long-term Economic Growth: Insights from the Chemical Industry.New York: John Wiley.
301. Musungu, F.S. and G. Dutfield (2003) ‘Multilateral agreements and a TRIPS-plus world: The World Intellectual Property Organization’. TRIPS Issues Paper 3. Geneva: Quaker United Nations Office.
302. Myers, G. (1995) ‘From discovery to invention: The writing and rewriting of two patents’. Social Studies of Science25(1): 57-105.
303. Nastelski, K. (1984) ‘Product protection for chemical inventions in Germany’. International Review of Industrial Property and Copyright Law 3(3): 267-294.
304. National Academies of Science, Board on Science, Technology, and Economic Policy (STEP), and Committee on Science, Technology, and Law (STL) (2005)Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health.Washington DC: NAS.
305. National Consumer Council (NCC) (1991)Intellectual Property: The Consumer View of Patents, Copyright, Trade Marks and Allied Rights (International Trade and the Consumer Working Paper 6). London: NCC.
306. Nature (editorial) (1995) ‘Names for hijacking’. Nature373: 370.
307. Nature Biotechnology (editorial) (2008) ‘Join the dots: Pushing biotech as the”solution” to the world’s problems is doing more harm than good’. Nature Biotechnology26(8): 837.
308. Neumann-Held, E.M. (2006) ‘The genetic code: Foundation of life or heuristic device’, in Max Planck-Institut für Wissenschaftsgeschichte, History and Epistemology of Molecular Biology and Beyond: Problems and Perspectives(Preprint 310). Berlin: MPIWG, 141-149.
309. Newman, D.J., G.M. Cragg and D.M. Snader (2002) ‘Natural products as sources of new drugs over the period 1981-2002’. Journal of Natural Products66: 1022-1037.
310. Newton, G.G.F. and E.P. Abraham (1955) ‘Cephalosporin C, a new antibiotic containing sulphur and D-a-aminoadipic acid’. Nature175: 548.
311. Nicolai, T.R. (1972) ‘First-to-file vs. first-to-invent: A comparative study based on German and United States patent law’. International Review of Industrial Property and Copyright Law3 (2): 103-139.
312. Noble, D. (2006)The Music of Life.Oxford: Oxford University Press.
313. Noble, D.F. (1977)America by Design: Science, Technology, and the Rise of Corporate Capitalism.New York: Alfred A. Knopf.
314. North, D.C. (1990)Institutions, Institutional Change and Economic Performance. Cambridge: Cambridge University Press.
315. Nuffield Council on Bioethics (2002)The Ethics of Patenting DNA: A Discussion Paper.London: Nuffield Council on Bioethics.
316. Office of Technology Assessment of the United States Congress (OTA) (1989)New Developments in Biotechnology: Patenting Life-Special Report. Washington DC: US Government Printing Office.
317. Olby, R. (1974)The Path to the Double Helix: The Discovery of DNA.Seattle: University of Washington Press.
318. Orbinski, J. (2001) ‘Health, equity, and trade: A failure in global governance’, in G.P. Sampson (Ed.), The Role of the World Trade Organization in Global Governance.Tokyo: United Nations University.
319. Organisation for Economic Cooperation and Development (OECD) (1996)National Accounts 1960-1994. Vol. 2, Detailed Tables.Paris: OECD.
320. Oudshoorn, N. (1990) ‘On the making of sex hormones: Research materials and the production of knowledge’. Social Studies of Science20(1): 5-33.
321. Owen, G. (1999)From Empire to Europe: The Decline and Revival of British Industry Since the Second World War. London: HarperCollins.
322. Owens, L. (1991) ‘Patents, the “frontiers” of American invention, and the Monopoly Committee of 1939: Anatomy of a discourse’. Technology and Culture32(4): 1076-1093.
323. Parascandola, J. (1985) ‘Industrial research comes of age: The American pharmaceutical industry, 1920-1940’. Pharmacy in History27(1): 12-21.
324. Parry, B. (2004)Trading the Genome: Investigating the Commodification of BioInformation.New York: Columbia University Press.
325. Parthasarathy, S. (2005) ‘Comparing genetic testing for breast cancer in the USA and the UK’. Social Studies of Science35(1): 5-40.
326. Patel, S. (1989) ‘Intellectual property rights in the Uruguay Round: A disaster for the South?’Economic and Political Weekly24: 978-993.
327. Paterson, G. (2002) ‘The creation of harmonised patent protection in Europe’, in H. Lawton-Smith (Ed.), The Regulation of Science and Technology.Basingstoke: Palgrave.
328. Payer, L. (1992)Disease-Mongers: How Doctors, Drug Companies, and Insurers are Making You Feel Sick.New York: John Wiley.
329. Payne, D.J. (2008) ‘Desperately seeking new antibiotics’. Science321: 1644-1645.
330. Pearson, H. (2006) ‘What is a gene?’Nature441: 399-401.
331. Penrose, E.T. (1951)The Economics of the International Patent System.Baltimore: Johns Hopkins University Press.
332. Perkin, W.H. (1915) ‘The position of the organic chemical industry’, in W.M. Gardner (Ed.), The British Coal-Tar Industry: Its Origin, Development and Decline. London: Williams and Norgate.
333. Peterson, D.H. (1985) ‘Autobiography’. Steroids45(1): 1-17.
334. Pharmaceutical Research and Manufacturers of America (PhRMA) (1998) ‘Industry profile. 1998 edition’. Washington: PhRMA.
335. Pharmaceutical Research and Manufacturers of America (PhRMA) (1999) ‘Annual report 1999-2000’. Washington: PhRMA.
336. Phillips, J. (2007) ‘The confusing case of Mr. Smith-Herchel Smith as litigant’, in Westkamp, G. (Ed.), Emerging Issues in Intellectual Property: Trade, Technology and Market Freedom: Essays in Honour of Herchel Smith. Cheltenham: Edward Elgar.
337. Picard, A. (2002) ‘Diabetics demand insulin safety probe’. The Globe and Mail6 February: 1.
338. Plotkin, M.J. (2000) Medicine Quest: In Search of Nature’s Healing Secrets. New York: Viking Penguin.
339. Pope, WJ. (1917) ‘The national importance of chemistry’, in A.C. Seward (Ed.), Science and the Nation. Cambridge: Cambridge University Press.
340. Porter, R. (1997)The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present.London: HarperCollins.
341. Powell, W.W. (1999) ‘The social construction of an organizational field: The case of biotechnology’. International Journal of Biotechnology1(1): 42-66.
342. Principe, P. (1998) ‘Economics and medicinal plants’, in T.R. Tomlinson and O. Olayiwola Akerele (Eds.), Medicinal Plants: Their Role in Health and Biodiversity.Philadelphia: University of Pennsylvania Press.
343. Public Citizen (2001) ‘Rx R&D myths: The case against the drug industry’s “R&D scare card”‘. Washington DC: Public Citizen.
344. Quigg, D.J. (1987) ‘Animals-Patentability’. Journal of the Patent and Trademark Office Society69(6): 328.
345. Quirke, V. (2005) ‘Making British cortisone: Glaxo and the development of corticosteroids in Britain in the 1950s-1960s’. Studies in History and Philosophy of Biological and Biomedical Sciences36: 645-674.
346. Rabinow, P. (1996)Making PCR: A Story of Biotechnology.Chicago: Chicago University Press.
347. Rai, A.K. (1999) ‘Intellectual property rights in biotechnology: Addressing new technology’. Wake Forest Law Review34: 827-847.
348. Rai, A. and J. Boyle (2007) ‘Synthetic biology: Caught between property right, the public domain, and the commons’. PLoS Biology5(3): e58.
349. Rainsford, K.D. (1999) ‘History and development of ibuprofen’, in K.D. Rainsford (Ed.), Ibuprofen: A Critical Bibliographic Review.London: Chapman and Hall, 1-24.
350. Rapp, R.T and R.P. Rozek (1990) ‘Benefits and costs of intellectual property protection in developing countries’. Journal of World Trade24(5): 75-102.
351. Rasmussen, N. (2002) ‘Steroids in arms: Science, government, industry, and the hormones of the adrenal cortex in the United States, 1930-1950’. Medical History46: 299-324.
352. Rasmussen, N. (2004) ‘The moral economy of the drug company-medical scientist collaboration in interwar America’. Social Studies of Science34(2): 161-185.
353. Reed, P. (1992) ‘The British chemical industry and the indigo trade’. British Journal for the History of Science25: 113-125.
354. Reekie, W.D. and M.H. Weber (1979)Profits, Politics and Drugs.London: Macmillan.
355. Regalado, A. (2001) ‘MIT researcher fueled genome-decoding race’. The Asian Wall Street Journal13 February: N4.
356. Reichman, J.H. and R.C. Dreyfuss (2007) ‘Harmonization without consensus: Critical reflections on drafting a substantive patent law treaty’. Duke Law Journal57: 85-130.
357. Reuters (2001a) ‘AstraZeneca holds off rivals as US patent on world’s top drug dies’. 6 October.
358. Reuters (2001b) ‘Bayer says US Cipro patent “beyond doubt”‘. 26 October.
359. Rickes, E.L., N.G. Brink, F.R. Koniuszy, T.R. Wood and K. Folkers (1948a) ‘Crystalline vitamin B12’. Science107: 396-397.
360. Rickes, E.L., N.G. Brink, F.R. Koniuszy, T.R. Wood, K. Folkers, N.G. Brink, F.R. Koniuszy, T.R. Wood and K. Folkers (1948b) ‘Comparative data on vitamin B12 from liver and from a new source, Streptomyces griseus’. Science108: 634-635.
361. Ricketson, S. (1987)The Berne Convention for the Protection of Literary and Artistic Works: 1886-1986, London: Queen Mary College Centre for Commercial Law Studies.
362. Ricupero, R. (2001) ‘Rebuilding confidence in the multilateral trading system: closing the “legitimacy gap”‘, in G.P. Sampson (Ed.), The Role of the World Trade Organization in Global Governance.Tokyo: United Nations University.
363. Rimmer, M. (2008)Intellectual Property and Biotechnology: Biological Inventions. Cheltenham: Edward Elgar.
364. Rivette, K.G. and D. Kline (2000) ‘Discovering new value in intellectual property’. Harvard Business Review (January-February): 54-66.
365. Robbins, L.J. (1961) ‘The proposed new European patent’. The Patent, Trademark, and Copyright Journal of Research and Education5 (3): 217-232.
366. Robbins-Roth, C. (2000)From Alchemy to IPO: The Business of Biotechnology. Cambridge: Perseus Publishing.
367. Roe, J.E. (1943) ‘War measures, the Alien Property Custodian and patents’. Journal of the Patent Office Society25(10): 692-728.
368. Rogan, J.E. (2002) ‘The global recognition of patents: An agenda for the 21st century’. Prepared for the WIPO Conference on the International Patent System, Geneva, 25-27 March.
369. Royal Society (2008) ‘Innovative mechanisms for tackling antibiotic resistance’. RS Policy Document 14/08. London: Royal Society.
370. Rubin, R.P. (2007) ‘A brief history of great discoveries in pharmacology: In celebration of the centennial anniversary of the founding of the American Society of Pharmacology and Experimental Therapeutics’. Pharmacological Reviews59(4): 289-359.
371. Ryan, M.P. (1998)Knowledge Diplomacy: Global Competition and the Politics of Intellectual Property.Washington DC: Brookings Institution Press.
372. Sager, A. and D. Socolar (2001) ‘Study ofjob data reveals drug makers’ priorities-Drug industry marketing staff soars while research staffing stagnates’. Boston: Boston University School of Public Health.
373. Sargant, M.G. (2003)Biomedicine and the Human Condition: Challenges, Risks, and Rewards.New York: Cambridge University Press.
374. Satchell, R.D. (1970) ‘Chemical product patent practice in the United Kingdom’. International Review of Industrial Property and Copyright Law1 (2): 179-189.
375. Scarpa, B. (1998) ‘Homage of a Sardinian to a Sardinian’. Abstract of the lecture given by Prof. Bachisio Scarpa in the occasion of the Symposium held in Cagliari (December 11-13, 1998) under the sponsorship of the Glaxo Wellcome. Downloadable fromhttp://pacs.unica.it/brotzu/.
376. Schatz, A., E. Bugie and S.A. Waksman (1944) ‘Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria’. Proceedings of the Society of Experimental Biological Medicine55: 66-69.
377. Scherer, F.M. and S. Weisburst (1995) ‘Economic effects of strengthening pharmaceutical patent protection in Italy’. International Review of Industrial Property and Copyright Law26(6): 1009-1024.
378. Schrodinger, E. (1944) What Is Life? Cambridge: Cambridge University Press.
379. Seigel, J. (2005)The Idea of Self: Thought and Experience in Western Europe Since the Seventeenth Century. Cambridge: Cambridge University Press.
380. Selgin, G. and J. Turner (2006) ‘James Watt as intellectual monopolist: Comment on Boldrin and Levine’. International Economic Review47: 1341-1348.
381. Sell, S.K. (1998)Power and Ideas: North-South Politics of Intellectual Property and Antitrust. Albany: State University of New York Press.
382. Sell, S.K. (1999) ‘Multinational corporations as agents of change: The globalization of intellectual property rights’, in A.C. Cutler, V. Haufler and T. Porter (Eds.), Private Authority and International Affairs.Albany: State University of New York Press.
383. Sell, S.K. (2003)Private Power, Public Law: The Globalization of Intellectual Property Rights.Cambridge: Cambridge University Press.
384. Senker, J. and P. van Zwanenberg (2001) ‘Final report: European biotechnology innovation systems’. Brussels: European Commission.
385. Service, R.F. (2004) ‘Surviving the blockbuster syndrome’. Science303: 1796-1799.
386. Shapiro, R. (2007) A simpler origin for life. Scientific American296(6), 24-31.
387. Sheehan, J.C. (1957) ‘The total synthesis of penicillin V’. Journal of the American Chemical Society79: 1262-1263.
388. Sheehan, J.C. (1982)The Enchanted Ring: The Untold Story.Cambridge: MIT Press.
389. Shiva, V. (1998)Biopiracy: The Plunder of Nature and Knowledge.Totnes: Green Books.
390. Silver, L. (2007) ‘Life 2.0’. Newsweek4 June.
391. Silverman, A. (1990) ‘Intellectual property law and the venture capital process’. High Technology Law Journal5(1): 157-192.
392. Simon, C. (1998) ‘The rise of the Swiss chemical industry reconsidered’, in E. Homburg, A.S. Travis and H.G. Schroter (Eds.), The Chemical Industry in Europe, 1850-1914: Industrial Growth, Pollution, and Professionalization. Dordrecht and Norwell: Kluwer Academic.
393. Slack, C. (2002)Noble Obsession: Charles Goodyear, Thomas Hancock, and the Race to Unlock the Greatest Industrial Secret of the Nineteenth Century.New York: Hyperion.
394. Slinn, J. (1995) ‘Research and development in the UK pharmaceutical industry from the nineteenth century to the 1960s’, in R. Porter and M. Teich (Eds.), Drugs and Narcotics in History. Cambridge: Cambridge University Press.
395. Slinn, J. (2008) ‘Patents and the UK pharmaceutical industry between 1945 and the 1970s’. History and Technology24(2): 191-205.
396. Smil, V. (2001)Enriching the Earth: Fritz Haber, Carl Bosch, and the Transformation of World Food Production.Cambridge and London: MIT Press.
397. Smith, E.L. (1948) ‘Purification of anti-pernicious anaemia factors from liver’. Nature161: 638-639.
398. Smith, J.B. and A.L. Willis (1971) ‘Aspirin selectively inhibits prostaglandin production in human platelets’. Nature New Biology231: 235-237.
399. Smith, R.G. and A. Barrie (1976)Aspro-How a Family Business Grew Up. Melbourne: Nicholas International.
400. Sneader, W. (1985)DrugDiscovery: The Evolution of Modern Medicines.Chichester, New York, Brisbane, Toronto, Singapore: John Wiley.
401. Sneader, W. (2005)Drug Discovery: A History.Chichester: John Wiley.
402. Stafford, N. (2004) ‘German biopatent law passed’. The ScientistDecember 10.
403. Starling, E.S. (1905) ‘The Croonian Lectures on the Chemical Correlation of the Functions of the Body. Lecture I’. The Lancet4275: 339-341.
404. Steele, H. (1962) ‘Monopoly and competition in the ethical drugs market’. Journal of Law and Economics5: 131-164.
405. Steen, K. (1995) ‘Confiscated commerce: American importers of German organic chemicals, 1914-1929’. History and Technology12: 261-284.
406. Stewart, F.C. (1919) ‘Letter to M.H. Coulston, President of the Patent Office Society’. Journal of the Patent Office Society2(1): 73-75.
407. Stigler, G. (1971) ‘The theory of economic regulation’. Bell Journal of Economics and Management Science2: 1-21.
408. Stix, G. (2001) ‘Staking claims’ (interview with Greg Aharonian). Scientific American 285(6): 22.
409. Stokes, G. (2001) ‘Patenting of genetic sequences: On the up and up’. IP MattersApril.
410. Stolz, R. and R. Schwaiberger (1987) ‘The correlation between dye chemistry and pharmacy in creating the modern chemotherapy’. History and Technology3: 193-203.
411. Stone, E. (1763) ‘An account of the success of the bark of the willow in the cure of agues. In a letter to the right Honourable George Earl of Macclesfield, President of the R.S. from the Rev. Edmund Stone, of Chipping-Norton in Oxfordshire’. Philosophical Transaction53.
412. Stone, T. and G. Darlington (2000)Pills, Potions and Poisons: How Drugs Work. Oxford: Oxford University Press.
413. Straus, J. (1998) ‘Biodiversity and intellectual property’. AIPPI Yearbook 1998. XXXVIIth Congress-Rio de Janeiro (May 24-29, 1998)-Workshops I-VII. Zurich: International Association for the Protection of Industrial Property.
414. Sulston, J. and G. Ferry (2002)The Common Thread: A Story of Science, Politics, Ethics and the Human Genome.London: Transworld Publishers.
415. Sung, L.M. and D.J. Pelto (1998) ‘The biotechnology patent landscape in the United States as we enter the new millennium’. Journal of World Intellectual Property1(6): 889-901.
416. Szpilfogel, S.A. and FJ. Zeelen (1996) ‘Steroid research at Organon in the golden 1950s and the following years’. Steroids61: 483-491.
417. Tansey, G. (2002) ‘TRIPS with everything: Intellectual property and the farming world’. London: Food Ethics Council.
418. Taylor, C.T. and Z.A. Silberston (1973)The Economic Impact of the Patent System: The British Experience.Cambridge: Cambridge University Press.
419. Temin, P. (1979) ‘Technology, regulation, and market structure in the modern pharmaceutical industry’. The Bell Journal of Economics10: 429-446.
420. ten Kate, K. and S.A. Laird (1999)The Commercial Use of Biodiversity: Access to Genetic Resources and Benefit Sharing.London: Earthscan.
421. Thomas, L.G. (1994) ‘Implicit industrial policy: The triumph of Britain and the failure of France in global pharmaceuticals’. Industrial and Corporate Change3(2): 451-489.
422. Tobin, B. (1997) ‘Certificates of origin: A role for IPR regimes in securing prior informed consent’, in J. Mugabe, C.V. Barber, G. Henne, L. Glowka and A. La Vina (Eds.), Access to Genetic Resources: Strategies for Sharing Benefits.Nairobi: ACTS Press.
423. Travis, A.S. (1993)The Rainbow Makers: Origins of the Synthetic Dyestuffs Industry in Western Europe.Lehigh: Lehigh University Press.
424. Tufts Center for the Study of Drug Development (2001) ‘Backgrounder: A methodology for counting costs for pharmaceutical R&D’. Boston: Tufts Center for the Study of Drug Development.
425. Uemura, S. (2000) ‘WIPO update: Patent law harmonization and the grace period’. CASRIP Publication Series: Rethinking Intellectual Property6: 263-270.
426. United Kingdom Board of Trade (1901)Report of the Committee Appointed by the Board of Trade to Inquire into the Working of the Patents Acts on Certain Specified Questions (‘The Fry Committee’).London: HMSO.
427. United Kingdom Board of Trade (1931)Report of the Departmental Commission on the Patents and Designs Acts and Practice of the Patent Office (‘The Sargant Committee’).London: HMSO.
428. United Kingdom Board of Trade(1947) Patents and Designs Acts. Final Report of the Departmental Committee (‘The Swan Committee’). London: HMSO.
429. United Kingdom Board of Trade(1970) The British Patent System: Report of the Committee to Examine the Patent System and Patent Law (‘The Banks Committee’). London: HMSO.
430. United Kingdom Department of Health (2001)Pharmaceutical Industry Competitiveness Task Force. Final Report-March 2001.London: Department of Health.
431. United Kingdom Ministry of Health (1967)Report of the Committee of Enquiry into the Relationship of the Pharmaceutical Industry with the National Health Service, 1954-1967 (‘The Sainsbury Committee’).London: HMSO.
432. United Nations Conference on Trade and Development (1974) ‘The role of the patent system in the transfer of technology to developing countries’. Geneva: UNCTAD.
433. United Nations Conference on Trade and Development (1975) ‘The international patent system as an instrument for national development’. Geneva: UNCTAD.
434. United Nations Conference on Trade and Development (2000) ‘Elements of a positive agenda’, in UNCTAD, Positive Trade Agenda for Developing Countries: Issues for Future Trade Negotiations.Geneva: UNCTAD.
435. United Nations Conference on Trade and Development-International Centre for Trade and Sustainable Development (2005)Resource Book on TRIPS and Development.Cambridge: Cambridge University Press.
436. United Nations Development Programme (1999)Human Development Report 1999.New York and Oxford: UNDP and Oxford University Press.
437. United States Patent and Trademark Office (2001) ‘Utility examination guidelines’. Federal Register66(4): 1092-1099.
438. USA Today (2001) ‘Cipro saga exposes how drugmakers protect profits’. 29 October: 14A.
439. Van den Belt, H. (1992) ‘Why monopoly failed: The rise and fall of Société La Fuschine’. British Journal for the History of Science25: 45-63.
440. Van den Belt, H. (1997)Spirochaetes, Serology and Salvarsan: Ludwik Fleck and the Construction of Medical Knowledge about Syphilis.Wageningen: Pensen and Looljen.
441. Van den Belt, H. and A. Rip (1989) ‘The Nelson-Winter-Dosi model and synthetic dye chemistry’, in WE. Bijker, T.P. Hughes and T. Pinch (Eds.), The Social Construction of Technological Systems.Cambridge: MIT Press.
442. Vane, J.R. (1971) ‘Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs’. Nature New Biology231: 232-235.
443. Vane, J.R. (1994) ‘Towards a better aspirin’. Nature367: 215-216.
444. Varma, A. and D. Abraham (1996) ‘DNA is different: Legal obviousness and the balance between biotech inventors and the market’. Harvard Journal of Law and Technology9: 53-85.
445. Vaughan, F.L. (1951) ‘Important differences in US and UK patent systems’. Journal of the Patent Office Society33(11): 779-799.
446. Veblen, T. (1923)Absentee Ownership and Business Enterprise in Recent Times. New York: Huebsch.
447. Venter, J.C. (2007) A Life Decoded.London: Allen Lane.
448. Venter, J.C. et al. (2001) ‘The sequence of the human genome’. Science291: 1304-1351.
449. Von Braun, J. (2008) Do public policy objectives have a space in the negotiation of bilateral free trade agreements? a study of multi-level diplomacy and the making of intellectual property law’ (PhD thesis). School of Law, Queen Mary, University of London.
450. Von Tunzelman, G.N. (1995)Technology and Industrial Progress: Foundations for Economic Growth.Cheltenham: Edward Elgar.
451. Wainwright, M. (1990)Miracle Cure: The Story of Penicillin and the Golden Age of Antibiotics.Oxford: Basil Blackwell.
452. Wainwright, M. (2004). ‘Photodynamic therapy-From dyestuffs to high-tech clinical practice’. Review of Progress in Coloration and Related Topics34: 95-109.
453. Warren-Jones, A. (2001)Patenting rDNA: Human and Animal Biotechnology in the United Kingdom and Europe.Witney: Lawtext Publishing.
454. Washburn, J. (2001) ‘Undue influence’. The American Prospect12: 14.
455. Watal, J. (2001)Intellectual Property Rights in the WTO and Developing Countries. New Delhi: Oxford University Press.
456. Watkins, K. (1992) ‘Battle for the rights to life’. The Guardian7 February: 29.
457. Watson, J.D. and F.H.C. Crick (1953) ‘A structure for deoxyribose nucleic acid’. Nature171: 737-738.
458. Weatherall, M. (1990) In Search of a Cure: A History of Pharmaceutical Discovery. Oxford: Oxford University Press.
459. Weiner, C. (1989) ‘Patenting and academic research: Historical case studies’, in V. Weil and J.W. Snapper (Eds.), Owning Scientific and Technical Information. New Brunswick and London: Rutgers University Press.
460. Weintraub, A. (2007) ‘Are pharmas addicted to lifestyle drugs?’BusinessWeekJune 15.
461. Wengenroth, U. (1997) ‘Germany: competition abroad-Cooperation at home, 1870-1900’, in A.D. Chandler, F. AmatoriandT. Hikino (Eds.), Big Business and the Wealth of Nations. Cambridge: Cambridge University Press.
462. Werth, B. (1994)The Billion-dollar Molecule: One Company’s Quest for the Perfect Drug.New York: Touchstone.
463. Williams-Jones, B. (2002) ‘History of a gene patent: Tracing the development and application of commercial BRCA testing’. Health Law Journal10: 123-146.
464. Wilmut, I., K. Campbell and C. Tudge (2000)The Second Creation: The Age of Biological Control by the Scientists Who Cloned Dolly.London: Headline Book Publishing.
465. Wimmer, W. (1998) ‘Innovation in the German pharmaceutical industry, 1880 to 1920’, in E. Homburg, A.S. Travis and H.G. Schroter (Eds.), The Chemical Industry in Europe, 1850-1914: Industrial Growth, Pollution, and Professionalization.Dordrecht and Norwell: Kluwer Academic.
466. Wishart, D.S., et al.(2007) ‘HMDB: The future metabolome database’. Nucleic Acids Research37: 521-526.
467. Wolfe, T.A. and B. Zycher (2005) ‘Biotechnological and pharmaceutical research and development investment under a patent-based access and benefit sharing regime’. San Francisco: Pacific Research Institute.
468. Woodmansee, M. (1984) ‘The Genius and the Copyright: Economic and Legal Conditions of the Emergence of the “Author”’. Eighteenth Century Studies17(4): 425-448.
469. Wooster, R., et al. (1995) ‘Identification of the breast cancer susceptibility gene BRCA2’. Nature378: 789-792.
470. World Health Organization (1996) ‘Investing in health research and development: Report of the ad hoc committee on health research relating to future intervention options’. Geneva: WHO.
471. World Health Organization (2005) ‘Genomics, genetics and the patenting of DNA: Review of potential implications for health in developing countries’. Geneva: WHO.
472. World Intellectual Property Organization (1999) ‘Protection of biological and genetic resources. Proposal by the Delegation of Colombia’ (SCP/3/10).
473. World Intellectual Property Organization (2000) ‘Matters concerning intellectual property and genetic resources, traditional knowledge and folklore. Document prepared by the Secretariat’ (WO/GA/26/6).
474. World Intellectual Property Organization (2004) ‘Proposal by Argentina and Brazil for the establishment of a development agenda for WIPO. Note prepared by the Secretariat’ (WO/GA/31/11).
475. World Intellectual Property Organization (2005a) ‘Provisions for the protection of traditional knowledge: Revised objectives and principles. Document prepared by the Secretariat’ (WIPO/GRTKF/IC/8/5).
476. World Intellectual Property Organization (2005b) ‘Provisions for the protection of traditional cultural expressions/expressions of folklore: Revised objectives and principles. Document prepared by the Secretariat’ (WIPO/GRTKF/IC/8/4).
477. World Intellectual Property Organization (2005c) ‘Proposal to establish a development agenda for the World Intellectual Property Organization (WIPO): An elaboration of issues raised in document WO/GA/31/11. Submission by the Group of Friends of Development’ (IIM/1/4).
478. World Intellectual Property Organization (2007) ‘Report of the Provisional Committee on Proposals Related to a WIPO Development Agenda’ (A/43/13 Rev.).
479. World Trade Organization (1998) ‘Preparations for the 1999 Ministerial Conference. General Council discussion on mandated negotiations and the built-in agenda, 23 November 1998. Communication from the United States’ (WT/GC/W/115).
480. World Trade Organization (1999a) ‘Preparations for the 1999 Ministerial Conference. EC approach to trade-related aspects of intellectual property in the new round. Communication from the European Communities’ (WT/GC/W/193).
481. World Trade Organization (1999b) ‘Preparations for the 1999 Ministerial Conference. proposal on trade-related aspects of intellectual property. Communication from Japan’ (WT/GC/W/242).
482. World Trade Organization (1999c) ‘Preparations for the 1999 Ministerial Conference. Implementation issues to be addressed before/at Seattle. Communication from Cuba, Dominican Republic, Egypt, El Salvador, Honduras, India, Indonesia, Malaysia, Nigeria, Pakistan, Sri Lanka and Uganda’ (WT/GC/W/354).
483. World Trade Organization (1999d) ‘Preparations for the 1999 Ministerial Conference. Implementation issues to be addressed in the first year of negotiations. Communication from Cuba, Dominican Republic, Egypt, El Salvador, Honduras, India, Indonesia, Malaysia, Nigeria, Pakistan, Sri Lanka and Uganda’ (WT/GC/W/355).
484. World Trade Organization (1999e) ‘Preparations for the 1999 Ministerial Conference. Proposals regarding the TRIPS Agreement (Paragraph 9(a)(ii) of the Geneva Ministerial Declaration). Communication from Venezuela’ (WT/GC/W/282).
485. World Trade Organization (1999f) ‘Preparations for the 1999 Ministerial Conference. Proposal on protection of the intellectual property rights relating to the traditional knowledge of local and indigenous communities. Communication from Bolivia, Colombia, Ecuador, Nicaragua, and Peru’ (WT/GC/W/362).
486. World Trade Organization (1999g) ‘Preparations for the 1999 Ministerial Conference. The TRIPS Agreement. Communication from Kenya on behalf of the African Group’ (WT/GC/W/302).
487. World Trade Organization (2000) ‘Canada-Patent protection of pharmaceutical products. Complaint by the European Communities and their Member States. Report of the panel’. (WT/DS114/R).
488. World Trade Organization (2001a) ‘TRIPS and public health. Submission by the Africa Group, Barbados, Bolivia, Brazil, Dominican Republic, Ecuador, Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, Philippines, Peru, Sri Lanka, Thailand and Venezuela’ (IP/C/W/296).
489. World Trade Organization (2001b) ‘Special discussion on intellectual property and access to medicines’ (IP/C/M/31).
490. World Trade Organization (2003) ‘Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: Decision of 30 August 2003’ (WT/L/540).
491. World Trade Organization (2005) ‘Amendment of the TRIPS Agreement: Decision of 6 December 2005’ (WT/L/641).
492. World Trade Organization (2006a) ‘The relationship between the TRIPS Agreement and the Convention on Biological Diversity: Summary of issues raised and points made. Note by the Secretariat. Revision’ (IP/C/W/368/Rev.1).
493. World Trade Organization (2006b) ‘Doha work programme-The outstanding implementation issue on the relationship between the TRIPS Agreement and the Convention on Biological Diversity. Communication from Brazil, India, Pakistan, Peru, Thailand and Tanzania’ (WT/GC/W/564).
494. Wright, S. (1986) ‘Recombinant DNA technology and its social transformation, 1972-1982’. Osiris 2nd Series2: 303-360.
495. Zigic, K. (2000) ‘Strategic trade policy, intellectual property rights protection, and North-South trade’. Journal of Development Economics61: 27-60.